为探究乳腺癌脑转移（BCBMs）治疗策略变化对患者结局的影响，意大利和法国多家机构研究人员开展相关研究。结果发现仅 HR-/HER2 + 患者总生存期改善。该研究对优化治疗、评估预后意义重大，值得科研读者一读。

美国食品药品监督管理局（FDA）已对zongertinib的新药申请给予优先审查，用于治疗肿瘤具有人类表皮生长因子受体2（HER2/ERBB2）突变且已接受过全身治疗的不可切除或转移性非小细胞肺癌（NSCLC）成年患者。

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

此外，在2024年世界肺癌大会上发表的数据还显示，zongertinib具有初步的脑活性。根据盲法独立中央审评（BICR）的评估，33%（120 mg，n=27）和40%（240 ...

HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...

2025 年 1 月 18 日，由北京市希思科临床肿瘤学研究基金会、杭州东方临床肿瘤研究中心共同主办的「2024 胃肠肿瘤年终大盘点」盛大召开。会议中揭榜 2024 胃肠领域十大临床热词，其中，肿瘤经典靶点人表皮生长因子受体 2（HER2）和抗 ...

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...

A new study on circulating tumor DNA (ctDNA) testing for advanced breast cancer has unveiled encouraging results, with high ...

Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.

The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...